for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NGM Biopharmaceuticals Inc

NGM.OQ

Latest Trade

17.15USD

Change

-0.29(-1.66%)

Volume

7,956

Today's Range

16.85

 - 

17.39

52 Week Range

9.54

 - 

23.93

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

NGM Biopharmaceuticals Inc Expands Oncology Portfolio With First Immuno-Oncology Development Candidate, Ngm707

Oct 19 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM EXPANDS ONCOLOGY PORTFOLIO WITH FIRST IMMUNO-ONCOLOGY DEVELOPMENT CANDIDATE, NGM707.NGM BIOPHARMACEUTICALS - PLANS TO INITIATE FIRST-IN-HUMAN TESTING OF NGM707 IN MID-2021.

NGM Bio Presents Findings From 24-Week Phase 2 Study (Cohort 4) Of Aldafermin And Announces Enrollment Completed In Phase 2B Alpine 2/3 Study

Aug 29 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO PRESENTS FINDINGS FROM 24-WEEK PHASE 2 STUDY (COHORT 4) OF ALDAFERMIN; ANNOUNCES ENROLLMENT COMPLETED IN PHASE 2B ALPINE 2/3 STUDY.NGM BIOPHARMACEUTICALS - 24-WEEK PHASE 2 STUDY MET ITS PRIMARY ENDPOINT, ACHIEVING A STATISTICALLY SIGNIFICANT REDUCTION IN LIVER FAT CONTENT (LFC).NGM BIOPHARMACEUTICALS - NEW ANALYSIS SHOWS 30% PLACEBO CORRECTED ANTI-FIBROTIC RESPONSE RATE AMONG NASH PATIENTS WITH MORE ADVANCED LIVER FIBROSIS.NGM BIO ANTICIPATES PHASE 2B ALPINE 2/3 STUDY TOPLINE DATA READOUT IN Q2 2021.

NGM Bio Reports Qtrly Loss Per Share Of $0.38

Aug 12 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO PROVIDES BUSINESS HIGHLIGHTS AND REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.NGM BIOPHARMACEUTICALS INC - $312.1 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF JUNE 30, 2020.NGM BIOPHARMACEUTICALS INC - .

NGM Biopharmaceuticals Files For Mixed Shelf Of Upto $400 Million

June 5 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIOPHARMACEUTICALS FILES FOR MIXED SHELF OF UPTO $400 MILLION - SEC FILING.

NGM Bio Appoints Siobhan Nolan Mangini As CFO

May 27 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO APPOINTS SIOBHAN NOLAN MANGINI AS CHIEF FINANCIAL OFFICER.NGM BIOPHARMACEUTICALS - NOLAN MANGINI MOST RECENTLY SERVED AS PRESIDENT AND CFO OF CASTLIGHT HEALTH.

NGM Biopharmaceuticals Posts Quarterly Loss Per Share $0.28

May 13 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.$328.5 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2020.NGM BIOPHARMACEUTICALS - RELATED PARTY REVENUE FROM COLLABORATION WITH MERCK FOR QUARTER ENDED MARCH 31, 2020 WAS $24.4 MILLION.QTRLY LOSS PER SHARE $0.28.IMPACT OF COVID-19 PANDEMIC, TO DATE, HAS NOT RESULTED IN A SIGNIFICANT IMPACT TO COMPANY'S DEVELOPMENT TIMELINES.REMAIN ON TRACK WITH ALL PREVIOUSLY PROVIDED CLINICAL TRIAL TIMING GUIDANCE.Q1 EARNINGS PER SHARE VIEW $-0.27, REVENUE VIEW $23.0 MILLION -- REFINITIV IBES DATA.

NGM Bio Reports Q4 Net Loss Per Share Of $0.24

March 17 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT HIGHLIGHTS.NGM BIOPHARMACEUTICALS - QTRLY NET LOSS PER SHARE $0.24.NGM BIOPHARMACEUTICALS - QTRLY RELATED PARTY REVENUE FROM COLLABORATION WITH MERCK WAS $31.1 MILLION VERSUS $47.1 MILLION.

Aetna Trombley To Step Down As President And COO Of NGM Biopharma

March 9 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::AETNA WUN TROMBLEY, PH.D. TO STEP DOWN AS PRESIDENT AND CHIEF OPERATING OFFICER OF NGM BIO TO ASSUME CHIEF EXECUTIVE OFFICER ROLE AT UNDISCLOSED PRIVATELY HELD COMPANY.NGM BIOPHARMACEUTICALS INC - TROMBLEY WILL CONTINUE WITH NGM ON A CONSULTING BASIS FOR AN INTERIM PERIOD.

NGM Bio Announces Positive Preliminary Topline Liver Histology And Biomarker Data From 24-Week Phase 2 Study Of Aldafermin In Nash Patients

Feb 24 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM BIO ANNOUNCES POSITIVE PRELIMINARY TOPLINE LIVER HISTOLOGY AND BIOMARKER DATA FROM 24-WEEK PHASE 2 STUDY (COHORT 4) OF ALDAFERMIN IN NASH PATIENTS, INCLUDING STATISTICALLY SIGNIFICANT ACHIEVEMENT OF COMPOSITE ENDPOINT OF BOTH FIBROSIS IMPROVEMENT AND RESOLUTION OF NASH VERSUS PLACEBO.NGM BIOPHARMACEUTICALS - CLINICALLY MEANINGFUL RESPONSE RATES OF 38% OF PATIENTS TREATED WITH ALDAFERMIN HAVING LIVER FIBROSIS IMPROVEMENT OF ≥1 STAGE.NGM BIOPHARMA - 22% OF ALDAFERMIN-TREATED PATIENTS VERSUS 0% PLACEBO ACHIEVED COMPOSITE ENDPOINT OF BOTH FIBROSIS IMPROVEMENT & RESOLUTION OF NASH.NGM BIOPHARMACEUTICALS - COHORT 4 POWERED TO DEMONSTRATE EFFECT OF ALDAFERMIN TREATMENT VERSUS PLACEBO, WHICH ACHIEVED STATISTICAL SIGNIFICANCE.NGM BIOPHARMA -STUDY ASSESSED SECONDARY ENDPOINTS OF LIVER HISTOLOGY, BIOMARKERS OF DISEASE ACTIVITY, MANY OF WHICH ACHIEVED STATISTICAL SIGNIFICANCE.NGM BIOPHARMA - PATIENTS TREATED WITH ALDAFERMIN DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN EACH OF NAFLD ACTIVITY SCORE COMPONENTS.NGM BIOPHARMACEUTICALS - STATISTICALLY SIGNIFICANT PROPORTION IN ALDAFERMIN TREATMENT ARM (62%) EXPERIENCED TWO-POINT IMPROVEMENT IN TOTAL NAS.NGM BIOPHARMACEUTICALS - NGM PLANS TO INITIATE PHASE 2B ALPINE 4 STUDY.

NGM Reports Third Quarter 2019 Financial Results

Nov 12 (Reuters) - NGM Biopharmaceuticals Inc <NGM.O>::NGM REPORTS BUSINESS HIGHLIGHTS AND THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 REVENUE $21.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $17.9 MILLION.-ANTICIPATES FULL COHORT 4 DATA, INCLUDING BIOPSY ASSESSMENTS, IN Q1 2020.CASH, CASH EQUIVALENTS AND SHORT-TERM MARKETABLE SECURITIES WERE $356.6 MILLION AS OF SEPTEMBER 30, 2019.QTRLY LOSS PER SHARE $0.17.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up